Luigi Mangione, the 28-year-old accused of fatally shooting UnitedHealthcare CEO Brian Thompson in New York City in December 2024, is expected to plead guilty in his federal case at a hastily scheduled court hearing on Friday — a development that could have sweeping consequences for a parallel state prosecution.
Mangione faces two federal charges of stalking resulting in death, each carrying a maximum sentence of life in prison. Prosecutors allege he travelled across state lines by bus, used a cellphone, the internet and interstate highways, and stayed at a hostel serving out-of-state customers while planning and carrying out the attack on Thompson, 50, who was shot from behind outside a Manhattan hotel on 4 December 2024 as he walked to UnitedHealth Group's annual investor conference. A person familiar with the matter, speaking anonymously to the Associated Press because they were not authorised to discuss the case publicly, cautioned that Mangione could still change his mind, and noted that previous plea talks broke down in June. Lawyers for Mangione and the Justice Department declined to comment ahead of the hearing.
The case against Mangione has been built on substantial physical evidence. When he was arrested five days after the shooting at a McDonald's in Altoona, Pennsylvania — roughly 370 kilometres west of Manhattan — police found a 3D-printed pistol in his backpack that investigators say matched the weapon used to kill Thompson, along with a notebook in which authorities allege he described his intent to kill an insurance executive. Surveillance footage showed a masked gunman shooting Thompson from behind; police say the words "delay," "deny" and "depose" — a phrase associated with tactics used by insurers to avoid paying claims — were written on the ammunition. A federal judge earlier this year removed the possibility of the death penalty but ruled that the backpack evidence could be used against him.
A guilty plea in the federal case would open a complex legal battle over the future of a separate state murder trial, currently scheduled to begin on 8 September. Under New York law, state double jeopardy protections can be triggered if a federal case ends in a guilty plea, provided the charges arise from the same course of conduct. Mangione himself argued in February that facing two trials amounted to double jeopardy "by any commonsense definition." State prosecutors, however, have pushed back in writing, arguing their case — which includes state homicide and firearms charges — is sufficiently distinct to proceed, and citing the "sanctity of life" principle underlying their charges.
The case has become a lightning rod in broader debates about the American health insurance industry. Mangione, an Ivy League graduate from a wealthy Maryland family, has attracted an unlikely public following among people frustrated with insurers, with supporters raising more than $1.5 million for his legal defence fund and appearing at court hearings in "FREE LUIGI" T-shirts. Legal analysts note that whatever the outcome of Friday's hearing, the double jeopardy question is, in the words of one white-collar defence attorney, "kind of a live issue" that will likely require further judicial rulings to resolve.